Axonics® System and SNM Therapy
About Urinary and Bowel Dysfunction
- Overactive bladder (OAB), bowel incontinence, and urinary retention are common conditions that can negatively impact quality of life, including work, social activities, exercise and sleep.1,2
- Overactive bladder is a dysfunction in which people experience frequent and urgent needs to empty their bladders. One of the most common symptoms of OAB is a sudden urge to urinate, resulting in unintentional urine loss.
- Bowel incontinence, or accidental bowel leakage, is a condition in which people are unable to control their bowel movements. People with this condition people experience sudden urges to pass stool and experience leakage of stool before they make it to the restroom.
- Urinary retention is the inability to empty the bladder. People with this condition are unable to urinate or feel frequent urges but only urinate in small amounts.
About the Axonics® System and SNM Therapy
- The Axonics System is the first rechargeable Sacral Neuromodulation (SNM) system for the treatment of overactive bladder, bowel incontinence and urinary retention.
- Axonics SNM Therapy provides gentle stimulation to the nerves that communicate between the brain, bladder and bowel. This advanced therapy restores normal communication, which can result in clinically significant symptom improvement
- Axonics SNM Therapy is indicated for patients who have not responded to more conservative treatments, including medications
- The Axonics System is small (about the size of a quarter) designed to last for at least 15 years and is full-body MRI compatible, reducing the need for device removal and replacement surgeries.
- The Axonics System offers the ability to trial the therapy with its External Trial System. The patient will wear a small and disposable device that fits discreetly under their clothing. Trialing the therapy allows physicians and their patients to experience first-hand if this therapy provides symptom reduction.
Clinically Proven Results
- The Axonics System is a clinically proven solution, in a clinical study with: 90% of patients experiencing clinically significant symptom improvements at 6 months post-implant.3
- 93% of patient were satisfied with their therapy.
- 92% of patients said they would undergo treatment again with the same expected results.
References: 1. Coyne KS, Sexton CC, Thompson CL, Milsom I, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJUI International. 2009;(104): 352-360. 2. Urology Care Foundation website: https://www.urologyhealth.org/urologic-conditions/overactive-bladder-(oab). Accessed February 20, 2019 3. McCrery R, Lane F, Benson K, Taylor C, Padron O, Blok B, Wachter S, Pezzella A, Gruenenfelder J, Pakzad M, Perrouin-Verbe MA, Le Normand L, Van Kerrebroeck P, Mangel J, Peters K, Kennelly M, Shapiro A, Lee U, Comiter C, Mueller M, Goldman HB. Treatment of urinary urgency incontinence using a rechargeable SNM system: 6-month results of the ARTISAN-SNM study. J Urol. E-publication ahead of print July 26, 2019.